<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01697293</url>
  </required_header>
  <id_info>
    <org_study_id>2011-269</org_study_id>
    <secondary_id>NCI-2013-01311</secondary_id>
    <secondary_id>11-051</secondary_id>
    <secondary_id>TCN-PM</secondary_id>
    <secondary_id>PTX-200-BC-1501.1</secondary_id>
    <secondary_id>PTX-200</secondary_id>
    <secondary_id>007884</secondary_id>
    <secondary_id>2011-269</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <secondary_id>R01CA098473</secondary_id>
    <nct_id>NCT01697293</nct_id>
  </id_info>
  <brief_title>PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer</brief_title>
  <official_title>A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prescient Therapeutics, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Prescient Therapeutics, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and the best dose of triciribine phosphate&#xD;
      when given together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide and to&#xD;
      see how well they work in treating patients with stage IIB-IV breast cancer. Triciribine&#xD;
      phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth. Drugs used in chemotherapy, such as paclitaxel, doxorubicin hydrochloride, and&#xD;
      cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing&#xD;
      the cells, by stopping them from dividing, or by stopping them from spreading. Giving&#xD;
      triciribine phosphate with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide may be&#xD;
      a better treatment for breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the recommended phase II dose of PTX-200 (triciribine phosphate) given on&#xD;
      days 1, 8, and 15 every 28 days (maximum of 9 doses) when combined with weekly paclitaxel (80&#xD;
      mg/m^2) for 12 weeks in patients with metastatic breast cancer. (Phase I and Expansion&#xD;
      Cohort) II. To determine the pathologic response rate (Residual Cancer Burden [RCB] score&#xD;
      0-1) after sequential weekly paclitaxel plus PTX 200 weekly, 3 weeks out of 4, followed by&#xD;
      doxorubicin (doxorubicin hydrochloride) (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2&#xD;
      weeks x 4 cycles in patients with clinical stage IIB-IIIC breast cancer. (Phase II).&#xD;
&#xD;
      III. To determine the feasibility and safety of the combination of sequential weekly&#xD;
      paclitaxel plus PTX-200 (days 1, 8, and 15) followed by doxorubicin/cyclophosphamide. (Phase&#xD;
      II)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To correlate pre-treatment levels of erb-b2 receptor tyrosine kinase (ErbB)1, 2, 3, 4 and&#xD;
      zinc finger protein 217 (ZNF217), and phosphorylated levels of v-akt murine thymoma viral&#xD;
      oncogene homolog 1 (Akt), signal transducer and activator of transcription 3 (acute-phase&#xD;
      response factor) (STAT3), extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) to&#xD;
      pathologic (RCB score 0-1) response (Sebti laboratory [lab]). (Phase I or II) II. To&#xD;
      correlate the percent decrease in the levels of phosphorylated (phospho-)Akt (S473),&#xD;
      phospho-S6 (S235-236), phospho-proline-rich Akt substrate, 40 kDa (PRAS40) (threonine&#xD;
      [Thr]246), phosphatase and tensin homolog (PTEN), Stathmin, pyruvate dehydrogenase kinase,&#xD;
      isozyme 1 (PDK1), cyclin D1, phospho-STAT3, ras homolog gene family, member C (Rho C), and&#xD;
      phospho-Erk 1-2 with pathologic response rate (RCB score 0-1), percent inhibition of&#xD;
      proliferation (Ki-67) and percent induction of apoptosis (terminal deoxynucleotidyl&#xD;
      transferase dUTP nick end labeling [Tunel]) (Sebti lab). (Phase I or II)&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of triciribine phosphate followed by an&#xD;
      expansion cohort and a phase II study.&#xD;
&#xD;
      COURSES A 1-12 (PHASE I &amp; II): Patients receive triciribine phosphate intravenously (IV) over&#xD;
      60 minutes on days 1, 8, and 15, 29, 36, 43, 57, 64, and 71 and paclitaxel IV over 1 hour on&#xD;
      days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 79. Treatment repeats every week for 12&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      COURSES B 1-4 (PHASE II): Patients receive doxorubicin hydrochloride IV over 5-10 minutes and&#xD;
      cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 4&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      SURGERY (PHASE II): Eligible patients undergo modified radical mastectomy, radical&#xD;
      mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or&#xD;
      biopsy.&#xD;
&#xD;
      After completion of study treatment, patients with metastatic disease are followed up every 3&#xD;
      months for 1 year and patients with locally advanced disease are followed up every 6 months&#xD;
      for 2 years and then yearly for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    criteria for continuing enrollment in Phase 2 portion was not met&#xD;
  </why_stopped>
  <start_date type="Actual">January 2012</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic response (RCB score 0-1), assessed using the criteria of Chevallier (Phase II)</measure>
    <time_frame>At time of surgery</time_frame>
    <description>The estimated pCR along with exact confidence interval will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II dose of triciribine phosphate, based on the incidence of dose-limiting toxicity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse effects will be summarized using frequency tables. The proportion of patients who completed all 12 courses of paclitaxel (at full dose or with dose modification) will be tabulated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical complete response and partial response, based on tumor measurements obtained by physical exam</measure>
    <time_frame>Up to 20 weeks (completion of courses B 1-4)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Breast Adenocarcinoma</condition>
  <condition>Estrogen Receptor Positive</condition>
  <condition>HER2/Neu Negative</condition>
  <condition>Recurrent Breast Carcinoma</condition>
  <condition>Stage IIB Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, surgery)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COURSES A 1-12 (PHASE I &amp; II): Patients receive triciribine phosphate IV over 60 minutes on days 1, 8, and 15, 29, 36, 43, 57, 64, and 71 and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 79. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
COURSES B 1-4 (PHASE II): Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
SURGERY (PHASE II): Eligible patients undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, surgery)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, surgery)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, surgery)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>Bristaxol</other_name>
    <other_name>Praxel</other_name>
    <other_name>Taxol</other_name>
    <other_name>Taxol Konzentrat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy</description>
    <arm_group_label>Treatment (chemotherapy, surgery)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triciribine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, surgery)</arm_group_label>
    <other_name>1, 5-Dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)-1,4,5, 6,8-pentaazaacenaphthylen-3-amine</other_name>
    <other_name>1,4, 5,6,8-Pentaazaacenaphthylen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)- (9CI)</other_name>
    <other_name>1,4,5,6, 8-Pentaazaacenaphthalen-3-amine, 1, 5-dihydro-5-methyl-1-(5-O-phosphono-.beta.-D-ribofuranosyl)-</other_name>
    <other_name>3-Amino-1, 5-dihydro-5-methyl-1-.beta.-D-ribofuranosyl-1,4,5,6, 8-pentaazaacenaphthylene 5'-(dihydrogen phosphate)</other_name>
    <other_name>TCN</other_name>
    <other_name>Triciribine</other_name>
    <other_name>Tricycloside Phosphate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Phase I and expansion cohort: Patients must have histologically or cytologically&#xD;
             confirmed adenocarcinoma of the breast associated with clinical stage: IV (see&#xD;
             American Joint Committee on Cancer [AJCC] staging criteria, 7th edition) or stage&#xD;
             IIB-IIIC (expansion cohort only)&#xD;
&#xD;
          -  Phase II: Patients must have histologically or cytologically confirmed adenocarcinoma&#xD;
             of the breast associated with the following clinical stage: IIB, IIIA, IIIB, or IIIC&#xD;
             (see AJCC staging criteria, 7th edition); the tumor must be human epidermal growth&#xD;
             factor receptor 2 (Her2)/neu negative (by DAKO HercepTest, fluorescence based in situ&#xD;
             hybridization [FISH], or other approved assay)&#xD;
&#xD;
          -  Phase I and expansion cohort: Up to two prior non-taxane chemotherapy regimens for&#xD;
             metastatic disease are permitted for patients enrolled on the phase I portion of the&#xD;
             trial; patients with HER2/neu positive breast cancer are not eligible; patients&#xD;
             treated with prior anthracycline therapy as neoadjuvant, adjuvant, or metastatic&#xD;
             therapy are not eligible unless the following conditions are met: (a) prior cumulative&#xD;
             doxorubicin dose is =&lt; 240 mg/m^2 (or epirubicin dose is =&lt; 400 mg/m^2), and (b) left&#xD;
             ventricular ejection fraction (LVEF) obtained at baseline is at least 50% (or &gt;= 5%&#xD;
             above lower institutional limits of normal whichever is higher); patients with&#xD;
             estrogen receptor (ER)-positive disease are required to have relapse or progression on&#xD;
             at least one line of endocrine therapy&#xD;
&#xD;
          -  Phase II: No prior chemotherapy, irradiation, or definitive therapeutic surgery (e.g.,&#xD;
             mastectomy or lumpectomy or axillary dissection) for this malignancy; patients who&#xD;
             have had a prior sentinel lymph node biopsy for this malignancy are eligible&#xD;
&#xD;
          -  Patients who received tamoxifen or another selective estrogen receptor modulator&#xD;
             (SERM) for prevention or treatment of breast cancer or for other indications (e.g.,&#xD;
             osteoporosis, prior ductal carcinoma in situ [DCIS]), or who receive aromatase&#xD;
             inhibitors for prevention or treatment of breast cancer, are eligible; patients who&#xD;
             are hormone-receptor positive and who have received other hormonal agents for the&#xD;
             treatment of breast cancer (e.g., Fulvestrant) are also eligible; tamoxifen therapy or&#xD;
             other hormonal agents should be discontinued at least 1 week before the patient is&#xD;
             enrolled on this study&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/uL&#xD;
&#xD;
          -  Absolute neutrophil count =&lt; 1,500/uL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/uL&#xD;
&#xD;
          -  Total bilirubin within normal institutional limits&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 2.5 x institutional&#xD;
             upper limit of normal&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) within normal institutional limits&#xD;
&#xD;
          -  Creatinine within normal institutional limits&#xD;
&#xD;
          -  LVEF at or above institutional lower limits of normal (&gt;= 50%), or at least 5% above&#xD;
             lower limits of normal if prior anthracycline exposure (by echocardiogram or nuclear&#xD;
             scan within 12 weeks of registration)&#xD;
&#xD;
          -  Electrocardiogram (ECG) corrected QT (QTC) &lt; 450 msec&#xD;
&#xD;
          -  Serum calcium within normal institutional limits&#xD;
&#xD;
          -  Serum phosphorus within normal institutional limits&#xD;
&#xD;
          -  Fasting glucose within normal limits&#xD;
&#xD;
          -  Patients must be disease-free of prior invasive malignancies for &gt;= 2 years with the&#xD;
             exception of curatively-treated basal cell or squamous cell carcinoma of the skin,&#xD;
             carcinoma in situ of the cervix (for phase II only); patients with the following prior&#xD;
             or concurrent diagnoses are eligible: lobular carcinoma in situ, contralateral ductal&#xD;
             carcinoma in situ, or contralateral invasive ductal and/or lobular cancer (and no&#xD;
             prior adjuvant chemotherapy for previous breast malignancy)&#xD;
&#xD;
          -  Women of childbearing potential must agree to use adequate contraception (hormonal or&#xD;
             barrier method of birth control) prior to study entry and for the duration of study&#xD;
             participation; should a woman become pregnant or suspect she is pregnant while&#xD;
             participating in this study, she should inform her treating physician immediately&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents during protocol&#xD;
             therapy, or up to 30 days prior to beginning protocol therapy; there should be a least&#xD;
             a 1-week interval between last dose of endocrine therapy and protocol therapy, and at&#xD;
             least 3 weeks for the last dose of biologic therapy (eg, bevacizumab) or cytotoxic&#xD;
             therapy (or 2 weeks for capecitabine or weekly paclitaxel, 6 weeks for mitomycin-C and&#xD;
             nitrosoureas), and adequately recovered from adverse effects from prior therapy to&#xD;
             meet all other eligibility criteria&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to PTX-200 or other agents used in the study (e.g., imidazoles,&#xD;
             quinolones)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, diabetes mellitus requiring therapy (insulin or oral hypoglycemic agents),&#xD;
             congenital prolonged QT syndrome, requirement for a drug known to prolong the QT&#xD;
             interval, a history of QT prolongation, a screening QTc &gt;= 450 msec,&#xD;
             hypertriglyceridemia requiring therapy, symptomatic congestive heart failure, unstable&#xD;
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study; breastfeeding should be discontinued if&#xD;
             the mother is treated with PTX-200; these potential risks may also apply to other&#xD;
             agents used in this study&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients receiving combination&#xD;
             antiretroviral therapy are excluded from the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Sparano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 13, 2012</study_first_submitted>
  <study_first_submitted_qc>September 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2012</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

